Veeva Systems (VEEV) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, VEEV broke through the 20-day moving average, which suggests a short-term bullish trend. The 20-day simple moving average is a popular investing tool. Traders like this SMA because it offers a look back at a stock's price over a shorter period and helps smooth out price fluctuations. The 20-day can also show more trend reversal signals than longer-term moving averages. Sim ...

Company Performance - Veeva Systems' shares have increased by 20.5% over the past three months, outperforming both the industry and the S&P 500 Index, driven by strong quarterly results, product expansion, and new partnerships [1] - The company reported a 15% increase in revenue year-over-year for the second quarter, with a 19% rise in recurring subscriptions, exceeding market expectations [2] - Veeva achieved a 32% improvement in operating profit and generated nearly $850 million in free cash flow during the first two quarters of fiscal 2025 [4] Revenue and Earnings Guidance - Veeva raised its revenue guidance for fiscal 2025 to between $2,704 million and $2,710 million, slightly above previous estimates [5] - Subscription revenues for fiscal 2025 are now expected to be $2,257 million, an increase from the prior outlook of $2,245 million [6] - Adjusted EPS for fiscal 2025 is projected to be $6.22, up from the previous guidance of $6.16 [7] New Partnerships and Product Developments - Veeva introduced new capabilities to its Veeva Site Connect, enhancing sponsor-site collaboration for clinical trials, which is expected to reduce trial time and costs [8] - The company partnered with Vita Global Sciences to enhance clinical data management, aiming for faster trials and improved patient outcomes [9] - Hangzhou Tigermed Consulting also signed a deal with Veeva to modernize electronic data capture and streamline data management processes [10] Industry Prospects - The global clinical data management system market is projected to grow from $2.3 billion in 2022 to $5.42 billion by 2030, at a CAGR of 11.3%, driven by an increase in clinical trials and integration with healthcare technologies [11]

The cloud software leader charged higher after a strong quarterly earnings report. Shares of Veeva Systems (VEEV 3.10%) rose 12.8% in August, according to data provided by S&P Global Market Intelligence. The company reported excellent quarterly financial results, and the stock's attractive valuation translated to gains as investors revised their forecasts higher. Veeva had a stellar quarterly report Veeva reported quarterly earnings on Aug. 28, sending the stock higher. The company achieved 15% revenue grow ...

Veeva Systems Inc. (VEEV) recently announced the newest release of Veeva Site Connect. The release adds powerful new capabilities and a streamlined site-centric experience to simplify and standardize sponsor-site collaboration, thus taking a major step forward for clinical trial execution. Per management, sponsors would be able to reduce the time and effort of site start-up, study conduct and closeout for higher-quality trials at a significantly lower cost with Veeva Site Connect. Following the release anno ...

Group 1: Zacks Premium Overview - Zacks Premium offers various tools for investors to enhance their stock market engagement, including daily updates on Zacks Rank and Industry Rank, access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens [1] - The service aims to help investors become more knowledgeable and confident in their investment decisions [1] Group 2: Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum characteristics, assisting investors in selecting stocks likely to outperform the market in the next 30 days [2] - Each stock receives a rating from A to F, with A indicating the highest potential for outperformance [3] Group 3: Value, Growth, and Momentum Scores - Value Score focuses on identifying undervalued stocks using ratios like P/E, PEG, and Price/Sales [4] - Growth Score evaluates a company's financial health and future outlook based on earnings, sales, and cash flow [4] - Momentum Score assesses stocks based on price trends and earnings estimate changes to identify favorable buying opportunities [4] Group 4: VGM Score - The VGM Score combines Value, Growth, and Momentum Scores, providing a comprehensive indicator for stock selection [5] Group 5: Zacks Rank and Performance - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in portfolio creation [6] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [7] Group 6: Stock Example - Veeva Systems (VEEV) - Veeva Systems Inc. specializes in cloud-based software applications for the life sciences sector, with products including Veeva CRM and Veeva Vault [10] - VEEV currently holds a 3 (Hold) rating on the Zacks Rank, with a VGM Score of B and a Momentum Style Score of B, having increased 19% in the past four weeks [11] - The Zacks Consensus Estimate for VEEV's fiscal 2025 earnings has risen by $0.06 to $6.21 per share, supported by upward revisions from eight analysts [11][12]

Did you analyze how Veeva Systems (VEEV) fared in its international operations for the quarter ending July 2024? Given the widespread global presence of this provider of cloud-based software services for the life sciences industry, scrutinizing the trends in international revenues becomes imperative to assess its financial strength and future growth possibilities. In the current global economy, which is more interconnected than ever, a company's success in penetrating international markets is crucial for it ...

The company is in the middle of a big transition. As a leading software company catering to the healthcare sector, Veeva Systems (VEEV 0.51%) has provided solid growth while operating in a defensive industry. The stock has had a good year, up over 10%, but it has trailed the market over the past five years even as management takes the business in a new direction. Let's dive into the company's most recent results and see if now is the time to buy the stock. Strong revenue growth For its fiscal second quarter ...

New capabilities and simple, standard site experience cut trial time and expense Fixed price implementation to get up and running quickly Industry advances to connected trials as seven of the top 20 biopharmas adopt Veeva Site Connect PLEASANTON, Calif., Sept. 5, 2024 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced, in a major step forward for clinical trial execution, the newest release of Veeva Site Connect, adding powerful new capabilities and a streamlined site-centric experience to simplify ...

Financial Performance - Total revenues for the three months ended July 31, 2024, were $676.2 million, a 14.6% increase from $590.2 million for the same period in 2023[7] - Subscription services revenue reached $561.3 million, up 19.2% from $470.6 million year-over-year[7] - Net income for the three months ended July 31, 2024, was $171.0 million, compared to $111.6 million for the same period in 2023, representing a 53.2% increase[7] - Operating income increased to $166.5 million, a 59.9% rise from $104.0 million in the prior year[7] - The company reported a gross profit of $505.8 million for the three months ended July 31, 2024, compared to $421.2 million for the same period in 2023[7] - Net income for the six months ended July 31, 2024, was $332,705,000, compared to $243,149,000 for the same period in 2023, representing a 37% increase[10] - Total revenues for the fiscal year ended January 31, 2024, reached $2,364 million, a 10% increase from $2,155 million in the previous fiscal year[64] - The company reported a net income of $526 million for the fiscal year ended January 31, 2024, compared to $488 million in 2023[64] Assets and Liabilities - Total current assets increased to $5.37 billion as of July 31, 2024, compared to $5.00 billion as of January 31, 2024[6] - Total assets reached $6.33 billion, an increase from $5.91 billion at the end of January 2024[6] - Total liabilities decreased to $1.15 billion from $1.27 billion in the previous reporting period[6] - The company’s total stockholders' equity increased to $5.18 billion as of July 31, 2024, from $4.64 billion at the end of January 2024[6] Cash Flow and Investments - Net cash provided by operating activities increased to $856,390,000 from $770,972,000, reflecting an 11% growth year-over-year[10] - Total cash, cash equivalents, and restricted cash at the end of the period was $1,167,932,000, up from $745,792,000, indicating a 56% increase[10] - The company reported a net cash used in investing activities of $386,220,000, a decrease from $916,324,000 in the previous year, showing a 58% improvement[10] - Cash, cash equivalents, and short-term investments totaled $4.9 billion as of July 31, 2024, with $67 million held outside the United States[99] Research and Development - Research and development expenses for the three months ended July 31, 2024, were $176.4 million, up 12.2% from $157.2 million in the same quarter last year[7] - The company anticipates an increase in the percentage of revenues derived from R&D Solutions in the future, reflecting a strategic focus on this area[63] Stock and Equity - The company issued 48,813 common shares upon the exercise of stock options, contributing an additional paid-in capital of $6,400,000[8] - Veeva Systems' additional paid-in capital increased to $2,117,109,000, up from $1,915,002,000 at the beginning of the period, marking an increase of approximately 11%[9] - The total number of common shares outstanding at the end of the period was 161,830,287, an increase from 161,624,611 at the beginning of the period[8] Tax and Compliance - Effective tax rates for the three months ended July 31, 2024, and 2023 were 24.0% and 21.9%, respectively, with a significant increase due to reduced excess tax benefits from equity compensation[31] - Future tax rates may be affected by changes in tax laws and regulations[92] - The effective tax rate may be adversely affected by changes in international operations and new tax rules, potentially harming future results[165] Legal and Regulatory Matters - The company has ongoing litigation with IQVIA, seeking injunctive relief and monetary damages exceeding $200 million due to alleged anticompetitive conduct[49] - The trial for IQVIA's trade secret claims is expected to begin on February 10, 2025[54] - The company is involved in ongoing legal proceedings, including a significant case against IQVIA regarding non-compete agreements, with a trial date set for June 13, 2025[117] Market and Competition - The company faces risks related to cybersecurity, including potential breaches that could harm customer trust and result in significant liabilities[121] - Competition is expected to intensify with the introduction of new technologies and potential new market entrants[122] - The company has limited experience selling certain data and analytics offerings, which may affect revenue growth[123] Customer Base and Revenue Sources - Subscription services revenues accounted for 83% of total revenues for the six months ended July 31, 2024, with professional services making up the remaining 17%[66] - The company served 1,432 customers as of January 31, 2024, up from 1,388 customers in 2023, indicating a growth in customer base[65] - Approximately 41% of total revenues in fiscal year ended January 31, 2024, came from customers outside North America[129] Operational Risks - The company faces significant risks in international operations, including localization costs and compliance with local laws[129] - The company may face increased scrutiny and pricing pressure during the renewal of large customer subscription orders[124] - The company has experienced difficulty attracting and retaining highly skilled employees, which may increase expenses[131] Future Outlook - The company expects revenue growth rates to accelerate in the fiscal year ending January 31, 2025, partly due to the prior year's contracting changes[152] - The company anticipates future expenses to increase due to investments in new solutions, technology infrastructure, and international expansion[157]

Veeva Systems Today | --- | --- | --- | --- | |--------------------------|-------|-------|-------| | | | | | | | | | | | VEEV | | | | | | | | | | Veeva Systems | | | | | $216.47 -0.55 (-0.25%) | | | | | 52-Week Range | | | | | $162.72 | | | | | ▼ | | | | | $236.90 | | | | | P/E Ratio | | | | | 63.86 | | | | | Price Target $230.13 | | | | | Add to Watchlist | | | | Shares of cloud-based software provider Veeva Systems Inc. NYSE: VEEV have been on a wild ride in the last year, surging by more than 40% from la ...